Marinomed Biotech AG is a pioneering biopharmaceutical company specializing in virology and immunology. Committed to transforming the lives of individuals with limited or no treatment options, Marinomed develops innovative therapies and unique solutions. Driven by curiosity and armed with patented technologies, the company explores unconventional paths in the pursuit of effective treatments.

By focusing on viral infectious diseases and autoreactive immune disorders, Marinomed is dedicated to creating therapies that address significant medical challenges. Marinomed's pipeline includes the development of medicinal products and medical devices designed to combat viral infectious diseases and autoreactive immune disorders. The company is proud of its track record of successful product and drug development in these areas.

Marinomed actively seeks strategic partnerships to join its mission of improving patient lives. As a publicly listed company on the prime market segment of the Vienna stock exchange, Marinomed is committed to delivering value to its investors while maintaining responsible business practices. With a track record of revenue growth, Marinomed continues to push forward business development activities and expand its impact in the field of biopharmaceuticals